Posted by Michael Wonder on 21 Oct 2020
NICE recommended use of Opdivo for another indication
20 October 2020 - This marks the tenth NICE recommendation for nivolumab.
Nivolumab is recommended as an option for the treatment of adults with locally advanced or metastatic squamous non-small-cell lung cancer after chemotherapy, only if:
- it is stopped at 2 years of uninterrupted treatment, or earlier if their disease progresses and
- they have not had a PD‑1 or PD‑L1 inhibitor before.
